Back to Trials
NCT07012135NARecruitingAccepts Healthy Volunteers

Deciphering Preserved Autonomic Function After Multiple Sclerosis

Mayo Clinic

Start Date

9/17/2025

Completion Date

12/31/2026

Summary

This study looks to characterize gradients of dysfunction in the autonomic nervous system in patients with clinically diagnosed multiple sclerosis. The autonomic nervous system plays key roles in regulation of blood pressure, skin blood flow, and bladder health- all issues that individuals with multiple sclerosis typically suffer. Focusing on blood pressure regulation, the most precise metric with broad clinical applicability, the investigators will perform laboratory-based tests to probe the body's ability to generate autonomic responses. For both individuals with multiple sclerosis and uninjured controls, laboratory-based experiments will utilize multiple parallel recordings to identify how the autonomic nervous system is able to inhibit and activate signals. The investigators anticipate that those with autonomic dysfunction with multiple sclerosis will exhibit abnormalities in these precise metrics. The investigators will look to see if any substantial connections exist between different degrees of preserved autonomic function and secondary autonomic complications from multiple sclerosis. In accomplishing this, the investigators hope to give scientists important insights to how the autonomic nervous system works after multiple sclerosis and give physicians better tools to manage these secondary autonomic complications.

Eligibility Criteria

Age Range: 18 years to 50 years

Inclusion Criteria: * 18-50 years old * clinically confirmed diagnosis of multiple sclerosis -OR- uninjured control Exclusion Criteria: * symptoms of cardiovascular (including, but not limited to: hypertension, stroke, chest pain, etc.), respiratory, peripheral neurological or autonomic disease (particularly diabetes mellitus requiring treatment) * women who are pregnant or lactating * having a body mass index (BMI) ≥ 35 kg/m2 * taking or being administered a medication known to potentially have adverse interactions with phenylephrine * in the judgement of the principal investigator or clinical collaborator, any illness or condition that will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results

Interventions

DIAGNOSTIC_TEST

Tests of sympathetic inhibition

DIAGNOSTIC_TEST

Tests of sympathetic activation

DIAGNOSTIC_TEST

Testing of autonomic dysreflexia

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Multiple SclerosisControl SubjectsAutonomic Dysreflexia

Locations

Mayo Clinic

Rochester, Minnesota 55902

United States